- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
India seeks corrective action from cough syrup firm Marion Biotech linked to Uzbek deaths
"The firm will not carry out any medicine manufacturing work until the final decision of the appellate authority,"Gupta said.
New Delhi: India's Uttar Pradesh state on Thursday said Marion Biotech, whose cough syrups Uzbekistan linked to the deaths of 65 children last year, will have to file a report of "corrective and preventive action" before being allowed to reopen its factory.
The statement from the state's drug controller came after Reuters on Wednesday reported an order from him dated Sept. 14, saying that an appeal from the company to restart the factory had been partially accepted. It said the company could resume production and sale of items that do not contain an ingredient linked to the cough syrup deaths, but did not give a timeline for resumption of production.
Read also: India allows cough syrup firm linked to Uzbek deaths to re-open factory
The drug controller, Shashi Mohan Gupta, said in the statement that the article was misleading and that the Uttar Pradesh government had asked Marion to file a report of Corrective and Preventive Action (CAPA) to address its shortcomings. Marion is based in the state near New Delhi.
That report will have to be verified by a team of inspectors from federal and state regulators, he said in the statement.
"The firm will not carry out any medicine manufacturing work until the final decision of the appellate authority," Gupta said.
Marion did not respond to a request for comment.
Marion is among three Indian companies whose cough syrups the World Health Organization and other agencies have linked to the deaths of 141 children in Uzbekistan, Gambia and Cameroon since the middle of last year, in one of the world's worst such waves of poisoning.
Gupta said in the September order seen by Reuters that the Uttar Pradesh government on Aug. 11 overturned cancellation of Marion's manufacturing licence by the state in March because "there's no known case of a lack of quality in other medicines manufactured by the firm".
"Its permission to make products using propylene glycol is cancelled, and it is allowed to make and sell all other products," the order read.
The company's production was suspended on Dec. 27 last year after Uzbekistan said Marion's Ambronol and DOK-1 Max syrups contained unacceptable amounts of toxins diethylene glycol (DEG) and ethylene glycol (EG), which are typically used in products not meant for human consumption.
Tests in January by an Indian government laboratory found 22 samples of Marion-made syrups were "adulterated and spurious," the country's drug controller said in March.
India's pharmaceuticals department told parliament the same month that tests had also shown that a sample of cough syrup-ingredient propylene glycol taken from Marion's factory contained EG.
Marion's then-head of operations, Tuhin Bhattacharya, earlier told Reuters the company had exported cough syrups for more than a decade without testing propylene glycol for impurities like DG or EG.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751